iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)

NCT05413369 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

582

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Insulin glargine/Lixisenatide
DRUG: IDegAsp
DRUG: Metformin
DRUG: SGLT2 inhibitor

Sponsor

Sanofi